ATE304528T1 - Verbindungen mit wachstumshormon-freisetzenden eigenschaften - Google Patents
Verbindungen mit wachstumshormon-freisetzenden eigenschaftenInfo
- Publication number
- ATE304528T1 ATE304528T1 AT01123155T AT01123155T ATE304528T1 AT E304528 T1 ATE304528 T1 AT E304528T1 AT 01123155 T AT01123155 T AT 01123155T AT 01123155 T AT01123155 T AT 01123155T AT E304528 T1 ATE304528 T1 AT E304528T1
- Authority
- AT
- Austria
- Prior art keywords
- compounds
- growth hormone
- hormone releasing
- releasing properties
- formula
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 102000018997 Growth Hormone Human genes 0.000 title abstract 2
- 108010051696 Growth Hormone Proteins 0.000 title abstract 2
- 239000000122 growth hormone Substances 0.000 title abstract 2
- 230000003578 releasing effect Effects 0.000 title 1
- 241001465754 Metazoa Species 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008267 milk Substances 0.000 abstract 1
- 210000004080 milk Anatomy 0.000 abstract 1
- 235000013336 milk Nutrition 0.000 abstract 1
- 230000001817 pituitary effect Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 210000002268 wool Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
- C07C281/06—Compounds containing any of the groups, e.g. semicarbazides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrrole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK80396 | 1996-07-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE304528T1 true ATE304528T1 (de) | 2005-09-15 |
Family
ID=8097747
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01123155T ATE304528T1 (de) | 1996-07-22 | 1997-07-17 | Verbindungen mit wachstumshormon-freisetzenden eigenschaften |
| AT97930368T ATE218537T1 (de) | 1996-07-22 | 1997-07-17 | Verbindungen mit wachstumshormon freisetzenden eigenschaften |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97930368T ATE218537T1 (de) | 1996-07-22 | 1997-07-17 | Verbindungen mit wachstumshormon freisetzenden eigenschaften |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US5922770A (de) |
| EP (2) | EP1184370B1 (de) |
| JP (1) | JP4425992B2 (de) |
| AT (2) | ATE304528T1 (de) |
| AU (1) | AU3434697A (de) |
| DE (2) | DE69713109T2 (de) |
| WO (1) | WO1998003473A1 (de) |
| ZA (1) | ZA976371B (de) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4116097B2 (ja) * | 1997-06-20 | 2008-07-09 | ノボ ノルディスク アクティーゼルスカブ | 成長ホルモン放出特性をもつ化合物 |
| US6127341A (en) * | 1997-06-20 | 2000-10-03 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| ES2331102T3 (es) * | 1998-05-11 | 2009-12-21 | Novo Nordisk A/S | Compuestos con propiedades de liberacion de la hormona del crecimiento. |
| TW450954B (en) * | 1998-05-14 | 2001-08-21 | Pharmacia & Amp Upjohn Company | Phenylsulfonamide-phenylethylamines useful as dopamine receptors |
| ATE500269T1 (de) * | 1998-06-30 | 2011-03-15 | Novo Nordisk As | Verbindungen mit wachstumshormon-freisetzenden eigenschaften |
| US6919315B1 (en) | 1998-06-30 | 2005-07-19 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| US6358951B1 (en) * | 1998-08-21 | 2002-03-19 | Pfizer Inc. | Growth hormone secretagogues |
| AU759022B2 (en) | 1999-02-18 | 2003-04-03 | Kaken Pharmaceutical Co., Ltd. | Novel amide derivatives as growth hormone secretagogues |
| UA73530C2 (uk) * | 1999-11-10 | 2005-08-15 | Ново Нордіск А/С | Сполука з властивостями вивільнювати гормон росту |
| US6992081B2 (en) | 2000-03-23 | 2006-01-31 | Elan Pharmaceuticals, Inc. | Compounds to treat Alzheimer's disease |
| DE60124080T2 (de) * | 2000-03-23 | 2007-03-01 | Elan Pharmaceuticals, Inc., San Francisco | Verbindungen und verfahren zur behandlung der alzheimerschen krankheit |
| US6613801B2 (en) * | 2000-05-30 | 2003-09-02 | Transtech Pharma, Inc. | Method for the synthesis of compounds of formula I and their uses thereof |
| ES2333097T3 (es) | 2000-05-31 | 2010-02-17 | Raqualia Pharma Inc | Uso de secretagogos de la hormona de crecimiento para estimular la motilidad gastrointestinal. |
| MXPA02012560A (es) | 2000-06-30 | 2003-05-14 | Elan Pharm Inc | Compuestos para tratar la enfermedad de alzheimer. |
| EP1666452A2 (de) | 2000-06-30 | 2006-06-07 | Elan Pharmaceuticals, Inc. | Verbindungen zur Behandlung der Alzheimerischen Krankheit |
| US6846813B2 (en) * | 2000-06-30 | 2005-01-25 | Pharmacia & Upjohn Company | Compounds to treat alzheimer's disease |
| US20030096864A1 (en) * | 2000-06-30 | 2003-05-22 | Fang Lawrence Y. | Compounds to treat alzheimer's disease |
| PE20020276A1 (es) | 2000-06-30 | 2002-04-06 | Elan Pharm Inc | COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER |
| CA2438367A1 (en) * | 2001-02-16 | 2002-08-29 | Allelix Neuroscience, Inc. | Thiophene substituted amine derivatives as glyt-1 inhibitors |
| EP1377295A4 (de) * | 2001-03-05 | 2007-05-09 | Transtech Pharma Inc | Carbonsäureamid-derivative als therapeutische mittel |
| AU2002245590B2 (en) * | 2001-03-05 | 2006-06-29 | Transtech Pharma, Inc. | Benzimidazole derivatives as therapeutic agents |
| US6982264B2 (en) * | 2001-06-27 | 2006-01-03 | Elan Pharmaceuticals, Inc. | Substituted alcohols useful in treatment of Alzheimer's disease |
| US20070213407A1 (en) * | 2001-06-29 | 2007-09-13 | Elan Pharmaceuticals And Pharmacia & Upjohn Company Llc | Compounds to treat Alzheimer's disease |
| EP1471054B1 (de) * | 2002-01-11 | 2009-07-01 | Daiichi Sankyo Company, Limited | Aminoalkoholderivat oder phosphonsäurederivat und diese enthaltende medizinische zusammensetzung |
| US7230133B2 (en) | 2003-05-01 | 2007-06-12 | Bristol-Myers Squibb Company | Malonamides and malonamide derivatives as modulators of chemokine receptor activity |
| BRPI0410436A (pt) * | 2003-05-20 | 2006-05-30 | Transtech Pharma Inc | antagonistas de rage como agentes para amiloidose reversa e doenças associadas com a mesma |
| US7476653B2 (en) | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
| WO2005027913A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue |
| KR20110136901A (ko) | 2004-02-24 | 2011-12-21 | 상꾜 가부시키가이샤 | 아미노 알코올 화합물 |
| KR20070010151A (ko) * | 2004-03-30 | 2007-01-22 | 사파이어 세라퓨틱스, 인크. | 성장 호르몬 분비촉진제를 이용하여 ｃ-반응성 단백질을감소시키는 방법 |
| EP2298760B1 (de) * | 2004-06-29 | 2015-08-05 | Helsinn Healthcare S.A. | Kristallformen von (3R)-1-(2-Methylalanyl-D-tryptophyl)-3-(phenylmethyl)-3-piperidin-carbonsäure-1,2,2-trimethylhydrazid |
| EP1789067B8 (de) * | 2004-08-12 | 2012-08-15 | Helsinn Healthcare S.A. | Verwendung von Wachstumshormon-sekretagoga zur Stimulierung der Motilität des gastrointestinalen Systems |
| WO2007023948A1 (ja) | 2005-08-25 | 2007-03-01 | Ube Industries, Ltd. | 光学活性（Ｓ又はＲ）－α－アミノ酸及び光学活性（Ｒ又はＳ）－α－アミノ酸エステルの製造方法 |
| CU23558A1 (es) | 2006-02-28 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento |
| WO2008095063A1 (en) | 2007-01-31 | 2008-08-07 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
| ES2604943T3 (es) | 2007-02-09 | 2017-03-10 | Ocera Therapeutics, Inc. | Moduladores macrocíclicos del receptor de la grelina y procedimientos de uso de los mismos |
| MX2009008561A (es) * | 2007-02-13 | 2010-01-15 | Helsinn Therapeutics Us Inc | Metodo para tratar trastornos proliferativos celulares utilizando secretagogos. |
| ES2430067T3 (es) | 2007-03-28 | 2013-11-18 | President And Fellows Of Harvard College | Polipéptidos cosidos |
| TWI429436B (zh) * | 2007-04-10 | 2014-03-11 | Helsinn Therapeutics Us Inc | 使用生長激素促泌素治療或預防嘔吐之方法 |
| UA105657C2 (uk) | 2009-02-27 | 2014-06-10 | Хелсінн Терапьютікс (Ю.Ес.), Інк. | Поліпшені способи лікування мігрені на основі анамореліну |
| TWI517850B (zh) | 2009-09-30 | 2016-01-21 | Ｖｔｖ治療有限責任公司 | 經取代之咪唑衍生物及其使用方法 |
| DK2603600T3 (da) | 2010-08-13 | 2019-03-04 | Aileron Therapeutics Inc | Peptidomimetiske makrocyklusser |
| CA2852468A1 (en) | 2011-10-18 | 2013-04-25 | Aileron Therapeutics, Inc. | Peptidomimetic macrocyles |
| HK1205454A1 (en) | 2012-02-15 | 2015-12-18 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
| SG10201606775YA (en) | 2012-02-15 | 2016-10-28 | Aileron Therapeutics Inc | Peptidomimetic macrocycles |
| US9717710B2 (en) | 2012-10-05 | 2017-08-01 | Vtv Therapeutics Llc | Treatment of mild and moderate Alzheimer's disease |
| CA2887285A1 (en) | 2012-11-01 | 2014-05-08 | Aileron Therapeutics, Inc. | Disubstituted amino acids and methods of preparation and use thereof |
| US9119832B2 (en) | 2014-02-05 | 2015-09-01 | The Regents Of The University Of California | Methods of treating mild brain injury |
| JP2017533889A (ja) | 2014-09-24 | 2017-11-16 | エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | ペプチド模倣大環状分子およびその使用 |
| JP2018516844A (ja) | 2015-03-20 | 2018-06-28 | エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | ペプチド模倣大環状分子およびその使用 |
| WO2017075535A1 (en) | 2015-10-28 | 2017-05-04 | Oxeia Biopharmaceuticals, Inc. | Methods of treating neurodegenerative conditions |
| EP3916817B1 (de) | 2016-02-09 | 2024-09-18 | Lumeova, Inc | Vorrichtungen und systeme zur ultrabreitbandigen, drahtlosen optischen hochgeschwindigkeitsübertragung |
| WO2019190823A1 (en) | 2018-03-28 | 2019-10-03 | Vtv Therapeutics Llc | Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine |
| WO2019190822A1 (en) | 2018-03-28 | 2019-10-03 | Vtv Therapeutics Llc | Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine |
| WO2020076668A1 (en) | 2018-10-10 | 2020-04-16 | Vtv Therapeutics Llc | Metabolites of [3-(4-{2-butyl-l-[4-(4-chloro-phenoxy)-phenyl]-lh-imidazol-4-yl } -phen ox y)-prop yl] -diethyl-amine |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69426206T2 (de) * | 1993-12-23 | 2001-05-17 | Novo Nordisk A/S, Bagsvaerd | Verbindungen mit wachstumshormonfreisetzenden eigenschaften |
| WO1996022997A1 (en) * | 1995-01-27 | 1996-08-01 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| PL327227A1 (en) * | 1995-12-22 | 1998-12-07 | Novo Nordisk As | Compounds exhibiting growth hormone liberating properties |
-
1997
- 1997-07-17 AT AT01123155T patent/ATE304528T1/de not_active IP Right Cessation
- 1997-07-17 AU AU34346/97A patent/AU3434697A/en not_active Abandoned
- 1997-07-17 WO PCT/DK1997/000314 patent/WO1998003473A1/en not_active Ceased
- 1997-07-17 JP JP50646598A patent/JP4425992B2/ja not_active Expired - Lifetime
- 1997-07-17 EP EP01123155A patent/EP1184370B1/de not_active Expired - Lifetime
- 1997-07-17 US US08/896,550 patent/US5922770A/en not_active Expired - Lifetime
- 1997-07-17 DE DE69713109T patent/DE69713109T2/de not_active Expired - Lifetime
- 1997-07-17 AT AT97930368T patent/ATE218537T1/de not_active IP Right Cessation
- 1997-07-17 DE DE69734215T patent/DE69734215T2/de not_active Expired - Lifetime
- 1997-07-17 EP EP97930368A patent/EP0923539B1/de not_active Expired - Lifetime
- 1997-07-18 ZA ZA9706371A patent/ZA976371B/xx unknown
-
1999
- 1999-03-17 US US09/270,862 patent/US6127354A/en not_active Expired - Lifetime
-
2000
- 2000-07-19 US US09/619,227 patent/US6274584B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998003473A1 (en) | 1998-01-29 |
| EP0923539B1 (de) | 2002-06-05 |
| DE69713109D1 (de) | 2002-07-11 |
| US6274584B1 (en) | 2001-08-14 |
| DE69734215D1 (de) | 2005-10-20 |
| JP4425992B2 (ja) | 2010-03-03 |
| AU3434697A (en) | 1998-02-10 |
| DE69734215T2 (de) | 2006-06-29 |
| EP1184370B1 (de) | 2005-09-14 |
| DE69713109T2 (de) | 2003-01-02 |
| EP0923539A1 (de) | 1999-06-23 |
| ATE218537T1 (de) | 2002-06-15 |
| EP1184370A3 (de) | 2002-03-27 |
| EP1184370A2 (de) | 2002-03-06 |
| US6127354A (en) | 2000-10-03 |
| US5922770A (en) | 1999-07-13 |
| JP2000515517A (ja) | 2000-11-21 |
| ZA976371B (en) | 1998-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE304528T1 (de) | Verbindungen mit wachstumshormon-freisetzenden eigenschaften | |
| MY113488A (en) | Compounds with growth hormone releasing properties | |
| RU94016393A (ru) | Пептиды, обладающие способностью к стимулированию высвобождения гормона роста, способ получения, фармацевтическая композиция, способ лечения | |
| DE69333607D1 (de) | Vorrichtung zur Herstellung von vorgefüllten, sterilen Abgabevorrichtungen | |
| ATE271874T1 (de) | Verwendung von inosine zur herstellung eines medikamentes zur stimulierung des axonwachstums von zns-neuronen | |
| SG158731A1 (en) | Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics | |
| SE9401406L (sv) | Farmaceutiska produkter för att bota tumörsjukdomar samt förfarande för framställning av desamma | |
| DE3382458D1 (de) | Haarwuchsmittel. | |
| DE69230112D1 (de) | Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin | |
| IT8619055A0 (it) | Composizioni farmaceutiche comprendenti peptidi del gruppo colecistochinina-cerulina per il trattamento terapeutico degli statidi shock e dell'insufficienza respiratoria e cardiocircolatoria. | |
| DK0562705T3 (da) | Anvendelse af L-deprenyl til fremstilling af et lægemiddel til behandling af Cushings sygdom | |
| DE60018409D1 (de) | Verwendung von antiseptika zur herstelllung von arzneimitteln zur prophylaxe und behandlung von infektionen und/ oder funktionellen gewebeumformungen im körperinneren | |
| DE69929616D1 (de) | Oxyhuminsäure und ihre verwendung zur behandlung von verschiedenenen störungen | |
| ATE136896T1 (de) | Piperidylmethyl substituierte chromanderivate als wirkstoffe zur behandlung von erkrankungen des zentralnervensystems | |
| GR3032224T3 (en) | Therapeutic agent for threatened abortion. | |
| DE69007065D1 (de) | Verwendung von Diadenosin-5',5'''-p1,p4-tetraphosphat zur Herstellung eines Arzneimittels zur Behandlung von Herzkrankheiten. | |
| DE69943239D1 (de) | Verbindungen mit wachstumshormon-freisetzenden eigenschaften | |
| CO4930262A1 (es) | Producto farmaceutico cristalino, su preparacion y uso como sustancia terapeutica | |
| NO166280C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive n,n'-disubstituerte ureaer. | |
| NO970185D0 (no) | Anvendelse av (S)-adenosyl-L-metionin (SAMe) og dets fysiologisk kompatible salter for behandling av reperfusjonsskade utlöst av temporær-fokal-ischemi | |
| AP1629A (en) | Drug delivery devices and methods for treatment of viral and microbial infections and wasting syndromes. | |
| RU2001113054A (ru) | Способ лечения послеродового острого гнойно-катарального эндометрита коров | |
| WO2001068693A8 (fr) | Nouveau polypeptide, proteine humaine de reception cannabinoide 7, et polynucleotide codant pour ce polypeptide | |
| RU2001123759A (ru) | Способ лечения одонтогенного остеомиелита, осложненного флегмоной | |
| FI935575A7 (fi) | 3-(kinolin-6-yylimetyyli)-4H-imidatsol-4-onijohdannaisia, menetelmä niiden valmistamiseksi ja niiden terapeuttinen käyttö |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |